Langzi Co., Ltd. (002612): Rapid growth in apparel and medical aesthetics, significant improvement in profitability
Core view: The company announced its 2023 financial results. According to financial reports, in 2023, the company achieved revenue of 5.145 billion yuan, +24.41% year-on-year, net profit of 225 million yuan to mother, +953.37% year-on-year, after deduction
Langzi Co., Ltd. (002612): Performance is in line with market expectations, clothing is steady, medical and aesthetic growth has achieved recovery
Investment highlights: The company released its 2023 annual report, and the performance is in line with market expectations. 1) Revenue in '23 was 5.145 billion yuan, up 24.41% year on year; net profit to mother was 225 million yuan, up 953.37% year on year; deducted
Debon Securities released a research report on April 24 stating that it gave Langzi Shares (002612.SZ) an increase in holdings rating. The main reasons for the rating include: 1) medical and aesthetic business: endogenous growth+epitaxial mergers and acqu
Debon Securities released a research report on April 24 stating that it gave Langzi Shares (002612.SZ) an increase in holdings rating. The main reasons for the rating include: 1) medical and aesthetic business: endogenous growth+epitaxial mergers and acquisitions help scale expansion, and the self-developed product matrix is gradually enriched; 2) Apparel business: positioning the middle and high-end markets, and new retail accelerates the online business layout. (Mainichi Keizai Shimbun)
Langzi Co., Ltd. (002612): Profitability improved markedly and continued high-quality growth in medicine and beauty
Incident: Langzi Co., Ltd. released its 2023 annual report. In 2023, the company achieved revenue of 5.145 billion yuan/ +24.41%, net profit to mother 225 million yuan/ +953.37%, after deducting 1.96 million yuan in net profit not attributable to mother
Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the
Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the women's clothing direct sales & online channels have achieved excellent growth; 3) the infant potential circuit continues to grow steadily, and the domestic market may be an important growth engine in the future; 4) continuous optimization on the rate side drives a significant increase in profitability. (Mainichi Keizai Shimbun)
Langzi Co., Ltd. (002612): Performance is in line with expectations, and the company continues to grow with high quality
Introduction to this report: All three businesses achieved rapid growth in 2023, and the company's net profit to mother increased 953% year over year; in 2024, the company will continue to promote endogenous and epitaxial expansion, and performance flexibility is expected to continue to be unleashed. Key investment points: investment and construction
Langzi Co., Ltd. (002612): Medical and aesthetic revenue increased 28% in '23, profitability recovered year on year
The 2023 results are in line with the previous forecast range, in line with our expectations. The company announced 2023 results: revenue of 5.145 billion yuan, +24.4% year-on-year after adjustment (same below); net profit of 225 million yuan (vs22)
Langzi Co., Ltd. (002612): Endogenous extension simultaneously helps medical and aesthetic growth and nurtures stores are expected to gradually reduce losses
The core view is that after retroactive adjustments were made to the merger of Wuhan Han Chen and Wuhan Wuzhou, the company's revenue in 2023 was +24.41%, of which the medical and aesthetic business was +27.8%, and endogenous extension simultaneously boosted revenue. At the same time, the company plans to share every 10 shares
Langzi Co., Ltd. (002612): Net profit due to mother increased 953% in 2023, medical and aesthetic business further expanded the chain layout
Seizing the opportunities for consumer recovery, the performance was good in 2023. The company achieved revenue of 5.145 billion yuan in 2023, an increase of 24.41% year on year, and net profit of 225 million yuan to mother, an increase of 953.37% year on year, less
Langzi Co., Ltd. (002612): The medical and aesthetic business is growing well, profitability is improving, and the nationwide layout is accelerating
The company achieved net profit of 225 million yuan (+953%) in 2023, in line with expectations. The company issued an annual report: achieved revenue of 5.145 billion yuan in 2023 (+24.4%, same below) and net profit to mother 2.
Langzi Co., Ltd. (002612.SZ) announced its 2023 annual results, with net profit of 225 million yuan, an increase of 953.37%
Langzi Co., Ltd. (002612.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 5...
Langzi Co., Ltd. (002612): Steady endogenous and epitaxial expansion, continuous release of performance flexibility
Guide to this report: The three major businesses grew rapidly in 2023, and the company's profit improved significantly; recently, the company plans to acquire Jimei, Zhengzhou, to continue to promote endogenous and epitaxial expansion, and performance flexibility is expected to continue to be unleashed in 2024. Key investment points: investment and construction
Express News | Langzi Co., Ltd.: The suspension of Douyin live streaming has basically had no impact on business development
The net profit of Akabang, an overseas holding subsidiary of Langzi Co., Ltd. (002612.SZ), increased 27.04% year-on-year in 2023 of 68.7012 million yuan
Langzi Co., Ltd. (002612.SZ) issued an announcement. Acabon Co., Ltd., an overseas holding subsidiary of the company (KO, Korea...
Langzi Co., Ltd. (002612.SZ): Not actively using short dramas to embed advertisements
Gelonghui, March 13 | Langzi Co., Ltd. (002612.SZ) said on the investor interactive platform that the company did not actively use skits to embed advertisements. The company's main brand, LANCY, invited Song Jia, the global brand ambassador, and LANCY FROM 25 invited brand ambassador Wang Churan to explain the brand's new products. At the same time, the company has carried out comprehensive advertising on mainstream online and offline channels, including embedded advertisements in TV series and movies. In the future, it will consider more ways to increase the promotion of the Langzi brand.
Langzi Co., Ltd. (002612): Proposed acquisition of Jimei, Zhengzhou to continue to accelerate the national layout of medical and aesthetic business
Core view: The company announced that it plans to acquire 100% of the shares in Jimei, Zhengzhou, in cash for 155 million yuan. According to the company's announcement, Beijing Langzi Medical Management, a wholly-owned subsidiary of the company, signed equity transfer agreements with Bochen 9, Wuhu Jujin, and Wu Hongming respectively. The total amount is proposed
Review of the Langzi Co., Ltd. (002612) incident: Proposed acquisition of Jimei, Zhengzhou, further the national layout
Incident: The company announced that it plans to acquire 100% of the shares in Jimei, Zhengzhou in cash, and that the transfer prices of 70%/18%/12% of the shares in Jimei, Zhengzhou are 1.08/0.28/0.19 billion yuan, respectively, for a total of 155 million yuan,
Langzi Co., Ltd. (002612): Proposed to acquire 100% of the shares in Jimei, Zhengzhou, and acquire medical and aesthetic mergers and acquisitions
Recent developments in the company On February 28, the company announced that its wholly-owned subsidiary, Beijing Langzi Medical Management, plans to acquire 70%, 18%, and 12% of the shares in Zhengzhou Jimei held by Bochen 9, Wuhu Jujin, and Wu Hongming respectively in cash. The share transfer prices are different.
Langzi Co., Ltd. (002612.SZ): Beijing Langzi Medical Management plans to acquire a total of 100% shares in Jimei, Zhengzhou
Gelonghui, Feb. 28, 丨 Langzi Co., Ltd. (002612.SZ) announced that on February 28, 2024, Beijing Langzi Medical Management and Wuhu Bochen No. 9 Equity Investment Partnership (“Bochen 9”), Wuhu Jujin Fashion Industry Investment Partnership (limited partnership) (“Wuhu Jujin”), and Wu Hongming have each signed an “Equity Transfer Agreement”. Beijing Langzi Medical Management plans to acquire Zhengzhou Beauty Healthcare held by Bochen 9, Wuhu Jujin, and Wu Hongming respectively in cash Hospital Co., Ltd. (“Zhengzhou Jimei” or “Target Company” for short) 70% , 18%, 12% equity
Langzi Co., Ltd. (002612.SZ): In the business of shaping and slimming
Gelonghui, February 22丨Langzi Co., Ltd. (002612.SZ) said on the investor interactive platform that the company has a slimming business, and you can consult the company's relevant medical and aesthetic agencies for specific projects and products.
No Data